Clinical Trial Update: A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating add-on Opicapone 50 mg or extra L-DOPA 100 mg for wearing-off in Parkinson disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• L-DOPA 100 mg (Levodopa)
• Opicapone 50 mg (Opicapone)

Snippet

Sponsor: SK Chemicals Co., Ltd. | Conditions: Parkinson Disease | Phase 4 | Status: COMPLETED